Clinical Trials

Aggregated clinical trials referenced across 278 hypotheses — linked to ClinicalTrials.gov

607
Unique Trials
262
Completed
135
Recruiting
278
Hypotheses
229,144
Total Enrolled

Phase Distribution

N/A
219
Phase II
163
Phase I
96
Unknown
48
Phase III
40
Phase IV
17
Phase I/II
8
Early Phase I
7
Observational
6
Phase II/III
3

Status Breakdown

Completed (262)Recruiting (135)Unknown (98)Active (38)Not Yet Recruiting (30)Terminated (24)Withdrawn (10)Enrolling (5)APPROVED_FOR_MARKETING (1)Available (1)Suspended (1)Halted (1)Planning (1)
Filter by Phase
Filter by Status
Showing 200 of 607 trials (sorted by hypothesis connections)
RAPA-501 Therapy for ALS
NCT04220190 Phase II Recruiting
Rapa Therapeutics LLC 41 enrolled 2025-01-02 → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral SclerosisRAPA-501 Autologous T stem cells
109
hypotheses
Perforant Path Presynaptic Terminal Protection StrategyReelin-Mediated Cytoskeletal Stabilization ProtocolHCN1-Mediated Resonance Frequency Stabilization Therapy+106 more
MAD Phase I Study to Investigate Contraloid Acetate
NCT03955380 Phase I Completed
Prof. Dr. Dieter Willbold 24 enrolled 2018-12-12 → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer DementiaAlzheimer DiseaseContraloid
109
hypotheses
Perforant Path Presynaptic Terminal Protection StrategyReelin-Mediated Cytoskeletal Stabilization ProtocolHCN1-Mediated Resonance Frequency Stabilization Therapy+106 more
Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury
NCT04820881 N/A Unknown
Washington D.C. Veterans Affairs Medical Center 60 enrolled 2021-10-01 → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
109
hypotheses
Perforant Path Presynaptic Terminal Protection StrategyReelin-Mediated Cytoskeletal Stabilization ProtocolHCN1-Mediated Resonance Frequency Stabilization Therapy+106 more
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease
NCT07212088 Phase I Not Yet Recruiting
iCamuno Biotherapeutics Ltd. 12 enrolled 2026-02-28 → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson DiseaseALC01 therapy
109
hypotheses
Perforant Path Presynaptic Terminal Protection StrategyReelin-Mediated Cytoskeletal Stabilization ProtocolHCN1-Mediated Resonance Frequency Stabilization Therapy+106 more
MRI Biomarkers in ALS
NCT02405182 N/A Completed
University of Alberta 145 enrolled 2014-09 → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral SclerosisALSMotor Neuron DiseasesMagnetic Resonance Imaging
109
hypotheses
Perforant Path Presynaptic Terminal Protection StrategyReelin-Mediated Cytoskeletal Stabilization ProtocolHCN1-Mediated Resonance Frequency Stabilization Therapy+106 more
An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Th
NCT06875739 Unknown Enrolling
Fondazione Don Carlo Gnocchi Onlus 310 enrolled 2025-02-14 → 2026-10-01
The aim of the study is to validate a salivary test that allows for rapid and accurate objective diagnosis in the context of neurodegenerative diseases, a complex of diseases that includes Alzheimer's
Neurodegenerative DisordersParkinson DiseaseAlzheimer Disease
27
hypotheses
Tau-Independent Microtubule Stabilization via MAP6 EnhancemeNetrin-1 Gradient RestorationGlycine-Rich Domain Competitive Inhibition+24 more
Cognitive-motor Training in Community-dwelling Older People With Mild Cognitive Impairment
NCT07241598 N/A Not Yet Recruiting
Mahidol University 70 enrolled 2025-12-01 → 2027-12-01
As the global population ages, the prevalence of mild cognitive impairment (MCI) among older adults, which ranges from 5% to 40%, is expected to rise. MCI significantly increases the risk of developin
Mild Cognitive Impairment (MCI)Smart±step cognitive-motor training
24
hypotheses
Gamma entrainment therapy to restore hippocampal-cortical syBeta-frequency entrainment therapy targeting PV interneuron-Closed-loop transcranial alternating current stimulation to +21 more
Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
NCT06206824 Phase I Recruiting
Perha Pharmaceuticals 164 enrolled 2024-01-18 → 2026-06
Leucettinib-21 First-in-Human Phase 1 Study in 6 Parts: Single (Part 1 and 5) and Multiple (Part 3 and 6) Ascending Doses, and Food-Effect (Part 2) in Healthy Subjects, and Single Dose (Part 4) in Peo
Healthy VolunteersDown SyndromeAlzheimer's DiseaseLeucettinib-21
24
hypotheses
Gamma entrainment therapy to restore hippocampal-cortical syBeta-frequency entrainment therapy targeting PV interneuron-Closed-loop transcranial alternating current stimulation to +21 more
The Effects of Exercise on Synaptic Plasticity in Individuals With Mild Cognitive Impairment and in Healthy Aging.
NCT05663918 N/A Unknown
McMaster University 36 enrolled 2023-02-13 → 2025-01-01
The research is focused on ameliorating cognitive decline in aging and in individuals diagnosed with Mild Cognitive Impairment (MCI). In the proposed research, we ask whether synaptic plasticity is mo
Mild Cognitive ImpairmentSelf- determined Intensity Interval Trai
24
hypotheses
Gamma entrainment therapy to restore hippocampal-cortical syBeta-frequency entrainment therapy targeting PV interneuron-Closed-loop transcranial alternating current stimulation to +21 more
Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis
NCT06339190 N/A Recruiting
Monash University 1,000 enrolled 2021-08-01 → 2025-12
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure level
Neurodegenerative DiseasesDementiaVenepuncture
21
hypotheses
Glycine-Rich Domain Competitive InhibitionLysosomal Membrane Repair EnhancementCryptic Exon Silencing Restoration+18 more
Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI
NCT04887675 N/A Unknown
University of Novi Sad 120 enrolled 2021-05-01 → 2022-06-01
Since the HIV changed its course to the chronic disease, high incidence of metabolic syndrome both in HIV positive and negative subjects has become an issue. Given the successful peripheral suppressio
HIV I InfectionHIV Associated LipodystrophyMetabolic SyndromeMRI
20
hypotheses
Tau-Independent Microtubule Stabilization via MAP6 EnhancemeNetrin-1 Gradient RestorationPiezoelectric Nanochannel BBB Disruption+17 more
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders
NCT00029965 Unknown Recruiting
National Human Genome Research Institute (NHGRI) 200 enrolled Started 2002-02-06
Study description: This is a natural history study that will evaluate any patient with enzyme or DNA confirmed GM1 or GM2 gangliosidosis, sialidosis or galactosialidosis. Patients may be evaluated ev
Neurological RegressionMyoclonusCherry Red Spot
20
hypotheses
Tau-Independent Microtubule Stabilization via MAP6 EnhancemeNetrin-1 Gradient RestorationPiezoelectric Nanochannel BBB Disruption+17 more
Retinal and Cognitive Dysfunction in Type 2 Diabetes
NCT04281186 Unknown Completed
Hospital Universitari Vall d'Hebron Research Insti 510 enrolled 2020-11-16 → 2024-12-12
The retina shares similar embryologic origin, anatomical features and physiological properties with the brain and hence offers a unique and accessible "window" to study the correlates and consequences
Retinal FunctionCognitive DysfunctionMicroperimetry
20
hypotheses
Tau-Independent Microtubule Stabilization via MAP6 EnhancemeNetrin-1 Gradient RestorationPiezoelectric Nanochannel BBB Disruption+17 more
A Noval Tau Tracer in Young Onset Dementia
NCT04248270 Phase I Unknown
Chang Gung Memorial Hospital 100 enrolled 2020-02-20 → 2023-08-17
Dementia is a clinical syndrome which characterized by progressive cognitive impairment, behavior disturbance and dysfunction of daily activity. In aging population, Alzheimer's dementia (AD) is the m
Alzheimer's DiseaseVascular DementiaDementia18F-PM-PBB3
20
hypotheses
Tau-Independent Microtubule Stabilization via MAP6 EnhancemeNetrin-1 Gradient RestorationPiezoelectric Nanochannel BBB Disruption+17 more
The Signature of Alzheimer's Disease in Subjective Cognitive Decline
NCT07402161 Unknown Recruiting
IRCCS Policlinico S. Donato 250 enrolled 2025-10-01 → 2027-10-01
This study focuses on improving early detection of Alzheimer's disease (AD) in patients with subjective cognitive decline (SCD), a preclinical stage of cognitive impairment, in the context of emerging
Subjective Cognitive Decline (SCD)Subjective Cognitive Complaints (SCCs)Subjective Cognitive Impairment
19
hypotheses
TREM2-mediated microglial tau clearance enhancementCell-Type Specific TREM2 Upregulation in DAM MicrogliaGFAP-Positive Reactive Astrocyte Subtype Delineation+16 more
Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's Disease
NCT06224920 N/A Completed
Ludwig-Maximilians - University of Munich 140 enrolled 2017-01-01 → 2024-01-01
The temporal sequence of microglial activation, changes in functional and structural connectivity and the progression of neurocognitive deficits has not been conclusively clarified. To date, there hav
Alzheimer DiseaseCorticobasal Syndromemagnetic resonance imagingelectroencephalographyblood and CSF biomarker
18
hypotheses
TREM2 Conformational Stabilizers for Synaptic DiscriminationTREM2-mediated microglial tau clearance enhancementCell-Type Specific TREM2 Upregulation in DAM Microglia+15 more
Clinical, Molecular and Electrophysiological Profiling of Parkinson's Disease: the Role of Non-pharmacological Therapies
NCT05807581 N/A Unknown
Fondazione Policlinico Universitario Agostino Geme 400 enrolled 2023-06-09 → 2025-05-30
In Parkinson's disease (PD), direct evidence linking inflammation to the harmful activities of alpha-synuclein (a-syn) aggregates, the disease onset, and its progression is still lacking. This transla
Parkinson Diseasephysical activityiTBS
15
hypotheses
TREM2 Conformational Stabilizers for Synaptic DiscriminationTREM2-Dependent Microglial Senescence TransitionTREM2-Mediated Selective Aggregate Clearance Pathway+12 more
Physical Activity in Patients With Parkinson's Disease: a "Disease Modifying" Intervention?
NCT05815524 N/A Terminated
Fondazione Policlinico Universitario Agostino Geme 30 enrolled 2022-05-02 → 2024-12-31
Parkinson's disease (PD) is a neurodegenerative disease characterized by bradykinesia, rigors, and tremor at rest. Distinctive neuropathological signs include progressive loss of dopaminergic neurons
Parkinson DiseasePhysical activity training
13
hypotheses
TREM2 Conformational Stabilizers for Synaptic DiscriminationTREM2-Dependent Microglial Senescence TransitionTREM2-Mediated Selective Aggregate Clearance Pathway+10 more
Search for Biomarkers of Neurodegenerative Diseases in Idiopathic REM Sleep Behavior Disorder
NCT04048603 N/A Unknown
Chinese University of Hong Kong 182 enrolled 2019-05-15 → 2022-03-31
This study is a prospective study with a mean of 7-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development
REM Sleep Behavior DisorderNeurodegeneration
13
hypotheses
Ferroptosis Inhibition for α-Synuclein NeuroprotectionPrime Editing Precision Correction of APOE4 to APOE3 in MicrPharmacogenomic CNS Drug Optimization Platform+10 more
Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema
NCT02227745 N/A Unknown
Hospital Juarez de Mexico 60 enrolled 2014-01 → 2015-03
Photocoagulation is the standard treatment in the focal EMCS, disrupts vascular leakage and allows the pigment epithelium remove the intraretinal fluid is effective in reducing the incidence of visual
Diabetic RetinopathyDiabetic Macular EdemaDorzolamide hydrochloride (2%)Placebo Sodium hyaluronate 4mg
13
hypotheses
Ferroptosis Inhibition for α-Synuclein NeuroprotectionPrime Editing Precision Correction of APOE4 to APOE3 in MicrPharmacogenomic CNS Drug Optimization Platform+10 more
Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's Disease
NCT04387812 N/A Unknown
Tel-Aviv Sourasky Medical Center 240 enrolled 2020-06-01 → 2023-12-31
Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye
Parkinson DiseaseGBA Gene MutationLeucine-rich Repeat Kinase 2 (LRRK2) GenXtrodes home PSG system
13
hypotheses
Ferroptosis Inhibition for α-Synuclein NeuroprotectionPrime Editing Precision Correction of APOE4 to APOE3 in MicrPharmacogenomic CNS Drug Optimization Platform+10 more
Ambroxol in Disease Modification in Parkinson Disease
NCT02941822 Phase II Completed
University College, London 23 enrolled 2016-12 → 2018-04
This study will evaluate the safety, tolerability and pharmacodynamics of ambroxol in participants with Parkinson Disease. Participants will administer ambroxol at five dose levels and will undergo cl
Parkinson DiseaseAmbroxol
13
hypotheses
Ferroptosis Inhibition for α-Synuclein NeuroprotectionPrime Editing Precision Correction of APOE4 to APOE3 in MicrPharmacogenomic CNS Drug Optimization Platform+10 more
Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism
NCT01759888 Phase II Completed
Chang Gung Memorial Hospital 49 enrolled 2011-08 → 2014-12
The primary objective of this protocol is to access the utility of 18F-DTBZ PET imaging as an in vivo biomarker to monitor neurodegeneration of both PD mouse models and PD patients. Secondary, the inv
Parkinson's Disease18F-DTBZ
13
hypotheses
Ferroptosis Inhibition for α-Synuclein NeuroprotectionPrime Editing Precision Correction of APOE4 to APOE3 in MicrPharmacogenomic CNS Drug Optimization Platform+10 more
Association of VAgus Nerve Stimulation and Treadmill Training for GAit Rehabilitation in DE Novo Parkinson's Disease
NCT07337226 N/A Not Yet Recruiting
Fondazione Policlinico Universitario Campus Bio-Me 60 enrolled 2026-01 → 2027-10
The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) can improve gait and brain function in people with diagnosis of idiopathic Parkinson's disease (
Idiopathic Parkinson's Disease (PD)Transcutaneous Auricular Vagus Nerve StiSham Transcutaneous Auricular Vagus NervConventional Physical Therapy (cPT)
10
hypotheses
RNA Granule Nucleation Site ModulationSelective Acid Sphingomyelinase Modulation TherapyAstrocyte-Mediated Neuronal Epigenetic Rescue+7 more
The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.
NCT04562831 N/A Active
Haukeland University Hospital 380 enrolled 2020-10-07 → 2026-10-31
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole, there is no effecti
Amyotrophic Lateral SclerosisEH301 (Nicotinamide Riboside/Pterostilbe
10
hypotheses
RNA Granule Nucleation Site ModulationSelective Acid Sphingomyelinase Modulation TherapyAstrocyte-Mediated Neuronal Epigenetic Rescue+7 more
Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
NCT00907283 Phase II Unknown
Ente Ospedaliero Ospedali Galliera 20 enrolled 2008-11 → 2024-12
This trial is a multicenter, unblinded, single-arm pilot study, lasting one year (plus one year extension Amendment n.3 25 August 2009, plus two years follow-up Amendment n.7) , to evaluate the effica
Neurodegenerative DiseaseIron OverloadDeferiprone
10
hypotheses
RNA Granule Nucleation Site ModulationSelective Acid Sphingomyelinase Modulation TherapyAstrocyte-Mediated Neuronal Epigenetic Rescue+7 more
Effect of the Vojta Therapy in Patients Multiple Sclerosis
NCT05558683 N/A Unknown
Aymara Abreu Corrales 25 enrolled 2022-12-01 → 2023-06-01
Multiple sclerosis is the most common disabling neurological disease in young adults. Inflammation, demyelination, neurodegeneration, gliosis and repair processes are involved in its process, which ar
Multiple SclerosisRandomized clinical trial.
10
hypotheses
RNA Granule Nucleation Site ModulationSelective Acid Sphingomyelinase Modulation TherapyAstrocyte-Mediated Neuronal Epigenetic Rescue+7 more
The Effect of RNS60 on ALS Biomarkers
NCT03456882 Phase II Completed
Mario Negri Institute for Pharmacological Research 147 enrolled 2017-05-30 → 2020-11-23
Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This prompts new treatment
Amyotrophic Lateral SclerosisRNS60
10
hypotheses
RNA Granule Nucleation Site ModulationSelective Acid Sphingomyelinase Modulation TherapyAstrocyte-Mediated Neuronal Epigenetic Rescue+7 more
PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With Machine Learning
NCT05569083 N/A Unknown
Azienda Ospedaliero-Universitaria Careggi 350 enrolled 2020-10-01 → 2023-09-30
Alzheimer's disease (AD) has a presymptomatic course which can last from several years to decades. Identification of subjects at an early stage is crucial for therapeutic intervention and possible pre
Cognitive DeclineMild Cognitive ImpairmentAlzheimer DiseaseGenetic analysis of APOE and BDNF genes.EEG recordingCSF collection and AD biomarker measurem
9
hypotheses
APOE4 Allosteric Rescue via Small Molecule ChaperonesCompetitive APOE4 Domain Stabilization PeptidesSelective APOE4 Degradation via Proteolysis Targeting Chimer+6 more
Deferiprone for Iron Reduction in Alzheimer's Disease
NCT03234686 Phase II Completed
Alzheimer DiseaseDeferiprone
8
hypotheses
ACSL4-Driven Ferroptotic Priming in Disease-Associated MicroLPCAT3-Mediated Lands Cycle Remodeling as the Primary FerropACSL4-Driven Ferroptotic Priming in Disease-Associated Oligo+5 more
Effect of Selenium on Mild Cognitive Impairment
NCT03533257 Phase II Completed
Mild Cognitive ImpairmentSelenomethionine
8
hypotheses
ACSL4-Driven Ferroptotic Priming in Disease-Associated MicroLPCAT3-Mediated Lands Cycle Remodeling as the Primary FerropACSL4-Driven Ferroptotic Priming in Disease-Associated Oligo+5 more
Pioglitazone in Alzheimer Disease (TOMORROW)
NCT00000145 Phase III Completed
Alzheimer DiseasePioglitazone
8
hypotheses
ACSL4-Driven Ferroptotic Priming in Disease-Associated MicroLPCAT3-Mediated Lands Cycle Remodeling as the Primary FerropACSL4-Driven Ferroptotic Priming in Disease-Associated Oligo+5 more
Vitamin E and Selenium in Preventing AD
NCT05081219 Phase II Recruiting
Alzheimer Disease PreventionVitamin ESelenium
8
hypotheses
ACSL4-Driven Ferroptotic Priming in Disease-Associated MicroLPCAT3-Mediated Lands Cycle Remodeling as the Primary FerropACSL4-Driven Ferroptotic Priming in Disease-Associated Oligo+5 more
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
NCT07392723 Phase II Recruiting
Michal Schnaider Beeri, Ph.D. 20 enrolled 2025-01-12 → 2027-04
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain va
Cognitive DysfunctionAlzheimer DiseaseBlood-Brain BarrierAlpha-Linolenic Acid (2.6 g/day)Placebo Control Group
7
hypotheses
APOE4 Allosteric Rescue via Small Molecule ChaperonesCompetitive APOE4 Domain Stabilization PeptidesSelective APOE4 Degradation via Proteolysis Targeting Chimer+4 more
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
NCT04838301 Phase II Recruiting
University of Arizona 100 enrolled 2023-08-15 → 2026-11-18
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Alzheimer DementiaLate Onset Alzheimer DiseaseNeurodegenerative DiseasesAllopregnanolonePlacebo
6
hypotheses
HSP90-Tau Disaggregation Complex EnhancementCell-Type Specific TREM2 Upregulation in DAM MicrogliaGFAP-Positive Reactive Astrocyte Subtype Delineation+3 more
Digital Evaluations and Technologies Enabling Clinical Translation for AD
NCT05385913 N/A Unknown
Oregon Health and Science University 200 enrolled 2022-04-01 → 2024-06-30
The DETECT-AD study (stands for "Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer's Disease") is a new study designed to improve clinical trials for early Alzheimer's d
Alzheimer Disease, Early OnsetMultivitamin-no intervention
5
hypotheses
APOE4 Allosteric Rescue via Small Molecule ChaperonesCompetitive APOE4 Domain Stabilization PeptidesSelective APOE4 Degradation via Proteolysis Targeting Chimer+2 more
Circadian Rhythm and Other Factors in Memory Clinic Patients
NCT05977712 N/A Recruiting
Assistance Publique - Hôpitaux de Paris 1,200 enrolled 2024-03-06 → 2027-03
The CIRCAME study is a bicentric study of patients from 2 memory clinics in Paris. The main objective is to identify circadian rhythm components and other individual risk factors (sociodemographic, be
DementiaQuestionnaireClinical examinationAccelerometer port
5
hypotheses
APOE4 Allosteric Rescue via Small Molecule ChaperonesCompetitive APOE4 Domain Stabilization PeptidesSelective APOE4 Degradation via Proteolysis Targeting Chimer+2 more
Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease
NCT02360527 N/A Completed
Hospital Universitari Vall d'Hebron Research Insti 126 enrolled 2014-09 → 2015-11
A clear association between type 2 diabetes (T2D) and Alzheimer's disease (AD) has been reported. This association is independent of vascular impairment, and therefore, it could be attributed to neuro
Retinal NeurodegenerationAlzheimer´s DiseaseType 2 Diabetes
5
hypotheses
APOE4 Allosteric Rescue via Small Molecule ChaperonesCompetitive APOE4 Domain Stabilization PeptidesSelective APOE4 Degradation via Proteolysis Targeting Chimer+2 more
Cognitive Functioning and Quality of Life in CNS Lymphoma
NCT00581737 N/A Completed
Memorial Sloan Kettering Cancer Center 50 enrolled 2000-07 → 2009-08
The purpose of this study is to evaluate several aspects of thinking abilities including attention and memory, and quality of life in patients who were diagnosed with and treated for Primary CNS Lymph
LymphomaCentral Nervous System Lymphoma
5
hypotheses
APOE4 Allosteric Rescue via Small Molecule ChaperonesCompetitive APOE4 Domain Stabilization PeptidesSelective APOE4 Degradation via Proteolysis Targeting Chimer+2 more
Effect of the Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia
NCT00502047 Phase II Completed
Rottapharm Spain 255 enrolled Started 2005-09
The hypothesis of this study is that soluble fibre may contribute to a reduction of the low density lipoprotein cholesterol (LDL-c), and the combined effect with a statin may achieve an optimisation o
HypercholesterolemiaCardiovascular DiseasePlantago ovata husk
5
hypotheses
APOE4 Allosteric Rescue via Small Molecule ChaperonesCompetitive APOE4 Domain Stabilization PeptidesSelective APOE4 Degradation via Proteolysis Targeting Chimer+2 more
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
NCT02689518 Phase IV Completed
University of California, San Diego 50 enrolled 2014-04 → 2019-11-12
Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)
Macular DegenerationWet Macular DegenerationIntravitreal aflibercept injection
5
hypotheses
APOE4 Allosteric Rescue via Small Molecule ChaperonesCompetitive APOE4 Domain Stabilization PeptidesSelective APOE4 Degradation via Proteolysis Targeting Chimer+2 more
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
NCT01928420 Phase II Completed
Humanetics Corporation 30 enrolled 2007-04 → 2014-06
The purpose of this study is to evaluate the safety and efficacy of NIC5-15 in the treatment of Alzheimer's Disease.
Alzheimer's DiseaseDementiaDrug: NIC5-15Placebo
5
hypotheses
APOE4 Allosteric Rescue via Small Molecule ChaperonesCompetitive APOE4 Domain Stabilization PeptidesSelective APOE4 Degradation via Proteolysis Targeting Chimer+2 more
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease
NCT00884507 Phase II Completed
Hoffmann-La Roche 389 enrolled 2009-05 → 2010-11
This 4 arm study will assess the efficacy and safety of RO5313534 (MEM3454) versus placebo added to donepezil, in patients with mild to moderate Alzheimer's disease. Following a screening period, pati
Alzheimer's DiseasePlaceboRO5313534RO5313534
5
hypotheses
HSP90-Tau Disaggregation Complex EnhancementCell-Type Specific TREM2 Upregulation in DAM MicrogliaGFAP-Positive Reactive Astrocyte Subtype Delineation+2 more
Effects of a Cognitive-Engaging Strength Training Program on Health, Physical Condition, and Quality of Life in People W
NCT07022431 N/A Not Yet Recruiting
University of Seville 34 enrolled 2025-10 → 2025-10
The primary objective of this project is to examine the impact of a strength training program with high cognitive demands on cognitive function, motor skills, physical fitness, and quality of life in
Alzheimer DiseaseInterval strength training
5
hypotheses
HSP90-Tau Disaggregation Complex EnhancementCell-Type Specific TREM2 Upregulation in DAM MicrogliaGFAP-Positive Reactive Astrocyte Subtype Delineation+2 more
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
NCT01066481 Phase II Withdrawn
Pfizer 2010-04 → 2012-03
The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease. It is a 6-month study enrolling 651 patients
Alzheimer's DiseaseDementiaDimebonPF-01913539 5 mgPF-01913539 5 mgPlacebo
5
hypotheses
HSP90-Tau Disaggregation Complex EnhancementCell-Type Specific TREM2 Upregulation in DAM MicrogliaGFAP-Positive Reactive Astrocyte Subtype Delineation+2 more
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
NCT01689246 Phase III Completed
TauRx Therapeutics Ltd 891 enrolled 2013-01 → 2015-11
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
Alzheimer's DiseaseTRx0237 150 mg/dayTRx0237 250 mg/dayPlacebo
5
hypotheses
HSP90-Tau Disaggregation Complex EnhancementCell-Type Specific TREM2 Upregulation in DAM MicrogliaGFAP-Positive Reactive Astrocyte Subtype Delineation+2 more
Omics of Rituximab-resistance
NCT07416942 N/A Not Yet Recruiting
Mario Negri Institute for Pharmacological Research 120 enrolled 2026-04 → 2029-03
The CONFUCIUS project aims to establish a personalised medicine framework for MN patients by integrating pharmacogenomics with other -omics technologies in order to identify biomarkers that predict re
Membranous NephropathyMulti-omics AnalysisSample collection
4
hypotheses
Complement C1q Subtype SwitchingDual-Domain Antibodies with Engineered Fc-FcRn Affinity ModuComplement C1q Mimetic Decoy Therapy+1 more
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
NCT04688788 Phase III Active
Rigshospitalet, Denmark 600 enrolled 2021-04-28 → 2026-05-05
The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.
Relapsing Remitting Multiple SclerosisSecondary Progressive Multiple SclerosisPrimary Progressive Multiple SclerosisRituximabOcrelizumabFexofenadine
4
hypotheses
Complement C1q Subtype SwitchingComplement C1q Mimetic Decoy TherapyLRP1-Dependent Tau Uptake Disruption+1 more
Amyotrophic Lateral Sclerosis (ALS) Families Project
NCT03865420 N/A Recruiting
Columbia University 300 enrolled 2018-09-11 → 2027-01
This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it pr
ALS
4
hypotheses
Glycine-Rich Domain Competitive InhibitionCryptic Exon Silencing RestorationCross-Seeding Prevention Strategy+1 more
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
NCT05269667 Phase IV Terminated
Hoffmann-La Roche 4 enrolled 2022-08-02 → 2023-10-26
Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previo
Neuromyelitis Optica Spectrum DisorderNMOSDSatralizumab 120 mg
4
hypotheses
Magnetosonic-Triggered Transferrin Receptor ClusteringGlymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation+1 more
Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From
NCT05908656 N/A Completed
Sanofi 13 enrolled 2024-04-02 → 2024-08-26
This is a three-phase study comprising both retrospective and prospective components, as follows: Phase I: Deployment of Rare Disease Algorithm: A diagnostic screening algorithm was developed using
Gaucher DiseaseInvestigational procedure
4
hypotheses
Selective Acid Sphingomyelinase Modulation TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic ProtectioSenescent Cell ASM-Complement Cascade Intervention+1 more
Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18
NCT02292654 Phase I Completed
Genzyme, a Sanofi Company 20 enrolled 2015-05-01 → 2019-12-09
Primary Objective: To evaluate the safety and tolerability of olipudase alfa administered intravenously in pediatric participants every 2 weeks for 64 weeks. Secondary Objective: To characterize th
Sphingomyelin LipidosisOlipudase alfa
4
hypotheses
Selective Acid Sphingomyelinase Modulation TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic ProtectioSenescent Cell ASM-Complement Cascade Intervention+1 more
Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase D
NCT02004691 Phase II Completed
Genzyme, a Sanofi Company 36 enrolled 2015-12-18 → 2021-03-15
Primary Objective: The primary objective of this phase 2/3 study was to evaluate the efficacy of olipudase alfa (recombinant human acid sphingomyelinase) administered intravenously once every 2 weeks
Sphingomyelin Lipidosisplacebo (saline)Olipudase alfa
4
hypotheses
Selective Acid Sphingomyelinase Modulation TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic ProtectioSenescent Cell ASM-Complement Cascade Intervention+1 more
Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipud
NCT05359276 Unknown Completed
Sanofi 40 enrolled 2022-06-10 → 2024-12-31
Primary Objective: To describe the lung, spleen and liver outcomes of olipudase alfa Secondary Objectives: * To describe the patient's characteristics * To describe conditions of olipudase alfa use
Acid Sphingomyelinase Deficiency (ASMD)Olipudase alfa
4
hypotheses
Selective Acid Sphingomyelinase Modulation TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic ProtectioSenescent Cell ASM-Complement Cascade Intervention+1 more
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase
NCT04877132 Unknown APPROVED_FOR_MARKETING
Sanofi
The objective of this program is to provide access to enzyme replacement therapy (ERT) with olipudase alfa for certain patients with ASMD, a severe, life threatening disease, that could not participat
Sphingomyelin Lipidosisolipudase alfa (GZ402665)
4
hypotheses
Selective Acid Sphingomyelinase Modulation TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic ProtectioSenescent Cell ASM-Complement Cascade Intervention+1 more
Dyslipidemia and Diabetic Retinopathy
NCT03403283 Unknown Completed
University of Alabama at Birmingham 45 enrolled 2014-01 → 2023-04-30
The purpose of this study is to determine if the reparative cells of blood vessels called endothelial progenitor cells(EPC) are defective in people with diabetes.
Diabetic RetinopathyDyslipidemia15 subjects with Non Proliferative DiabeHealthy Controls 15 age matched control
4
hypotheses
Selective Acid Sphingomyelinase Modulation TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic ProtectioSenescent Cell ASM-Complement Cascade Intervention+1 more
Efavirenz for Patients With Alzheimer's Disease
NCT03706885 Phase I Completed
Case Western Reserve University 5 enrolled 2018-05-05 → 2022-01-28
This will be a two-center, placebo controlled blinded clinical trial to evaluate the safety and tolerability of efavirenz (EFV) in 36 clinically stable subjects with mild cognitive impairment/early de
Alzheimer Disease, Early OnsetSustiva Pill
4
hypotheses
CYP46A1 Overexpression Gene TherapyCholesterol-CRISPR Convergence Therapy for NeurodegenerationCYP46A1 Suppression for Tau-Mediated Neurodegeneration+1 more
Effect of CT1812 Treatment on Brain Synaptic Density
NCT03493282 Phase I Completed
Cognition Therapeutics 43 enrolled 2018-03-28 → 2020-10-16
Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
Alzheimer DiseaseActive Treatment- CT1812 100 mgActive Treatment- CT1812 300 mgPlacebo
4
hypotheses
Synaptic Vesicle Tau Capture InhibitionPrefrontal sensory gating circuit restoration via PV interneHippocampal CA3-CA1 circuit rescue via neurogenesis and syna+1 more
The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA
NCT05005637 Phase II Completed
Fakultas Kedokteran Universitas Indonesia 78 enrolled 2021-08-27 → 2024-10-20
The reported incidence of uveitis is 52 persons per year per 100,000 population, with a greater incidence estimated in developing countries, including Indonesia. Uveitis has challenges in diagnosis an
Tuberculous UveitisAnti Tuberculosis DrugMethylprednisolone
3
hypotheses
Complement C1q Subtype SwitchingComplement C1q Mimetic Decoy TherapyComplement C1QA Spatial Gradient in Cortical Layers
Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia
NCT05093192 N/A Completed
University of Bath 26 enrolled 2021-10-01 → 2022-12-06
Chronic lymphocytic leukaemia (CLL) is the most common adult blood cancer in the United Kingdom. CLL means that many cancer cells appear in the blood, bone marrow and other tissues, for example, the s
Chronic Lymphocytic LeukemiaMinimal Residual DiseaseExercise trial
3
hypotheses
Complement C1q Subtype SwitchingComplement C1q Mimetic Decoy TherapyComplement C1QA Spatial Gradient in Cortical Layers
Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study
NCT02120482 N/A Terminated
Medical University of Vienna 4 enrolled 2014-10 → 2022-07-31
Recipient desensitization is a prerequisite for successful ABO-incompatible kidney transplantation (ABOi-KTX). Published desensitization protocols commonly include the use of plasmapheresis or selecti
Decreased Immunologic ActivityAntibody-mediated RejectionCombined apheresis
3
hypotheses
Complement C1q Subtype SwitchingComplement C1q Mimetic Decoy TherapyComplement C1QA Spatial Gradient in Cortical Layers
Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function
NCT02460783 N/A Completed
National Institute on Aging (NIA) 129 enrolled 2015-06-22 → 2022-01-14
Background: \- Insulin removes sugar from the blood to use for energy. Insulin resistance means that cells may not respond to insulin normally. It can lead to serious diseases. Researchers want to se
Alzheimer's DiseaseObesityDiabetes MellitusBoost (R) 5-2 dietHealthy Living Diet
3
hypotheses
Glycine-Rich Domain Competitive InhibitionCryptic Exon Silencing RestorationCross-Seeding Prevention Strategy
Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS
NCT07095712 Phase I Active
n-Lorem Foundation 1 enrolled 2024-11-25 → 2025-11
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in
Amyotrophic Lateral SclerosisnL-TARD-001
3
hypotheses
Glycine-Rich Domain Competitive InhibitionCryptic Exon Silencing RestorationCross-Seeding Prevention Strategy
Amyotrophic Lateral Sclerosis Registry in Thailand
NCT07175935 N/A Recruiting
Chulalongkorn University 100 enrolled 2025-03-01 → 2030-12-31
This is a prospective, observational, multicenter registry designed to collect comprehensive clinical, genetic, and outcome data from patients diagnosed with amyotrophic lateral sclerosis (ALS) across
ALS (Amyotrophic Lateral Sclerosis)
3
hypotheses
Glycine-Rich Domain Competitive InhibitionCryptic Exon Silencing RestorationCross-Seeding Prevention Strategy
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
NCT05189106 Phase I Completed
Massachusetts General Hospital 17 enrolled 2022-12-05 → 2025-04-24
This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (AL
Amyotrophic Lateral SclerosisAlzheimer DiseaseMild Cognitive ImpairmentBaricitinib
3
hypotheses
Glycine-Rich Domain Competitive InhibitionCryptic Exon Silencing RestorationCross-Seeding Prevention Strategy
Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS
NCT05852405 N/A Completed
Ambulanzpartner Soziotechnologie APST GmbH 2,000 enrolled 2021-08-01 → 2024-12-31
Patients with sporadic ALS (sALS), which refers to those without a family history of ALS, are typically not subjected to genetic investigations as part of their standard care. Therefore, their mutatio
Motor Neuron Disease, Amyotrophic Latera
3
hypotheses
Glycine-Rich Domain Competitive InhibitionCryptic Exon Silencing RestorationCross-Seeding Prevention Strategy
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
NCT04330820 Phase I Unknown
Technische Universität Dresden 55 enrolled 2020-04-06 → 2023-10-11
This is an open-label Phase I dose-escalation study of oral venetoclax in combination with increasing cytarabine doses plus mitoxantrone to define the safety profile and MTD of cytarabine in subjects
Relapsed Adult AMLRefractory AMLVenetoclax Oral Tablet
3
hypotheses
Epigenetic Memory Erasure via TET2 ActivationPericyte Contractility Reset via Selective PDGFR-β AgonismTET2-Mediated Demethylation Rejuvenation Therapy
Neuroinflammation in FTLD
NCT06870838 N/A Active
Leiden University Medical Center 110 enrolled 2023-07-25 → 2025-08-01
The goal of this observational study is to investigate the role of neuroinflammation in frontotemporal lobar degeneration (FTLD). The main aims of this study are: 1. To elucidate the role and timing
Corticobasal Syndrome(CBS)Primary Progressive Aphasia(PPA)Progressive Supranuclear Palsy(PSP)7T MRI scanCSFBlood withdrawal
3
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 DysregulationTREM2 Conformational Stabilizers for Synaptic Discrimination
TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics.
NCT07399418 N/A Recruiting
Istituti Clinici Scientifici Maugeri SpA 80 enrolled 2025-09-01 → 2027-07-31
The study is based on the hypothesis that the integration of biological, psychological, and social factors, according to the biopsychosocial paradigm, allows for more accurate identification of the di
Cognitive Decline
3
hypotheses
Temporal Decoupling via Circadian Clock ResetCircadian Clock-Autophagy SynchronizationGFAP-Positive Reactive Astrocyte Subtype Delineation
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Pat
NCT02906020 Phase II Terminated
Genzyme, a Sanofi Company 273 enrolled 2016-12-15 → 2020-12-18
Primary Objectives: * Part 1: To determine the safety and tolerability of 4, 8, and 15 milligrams of GZ/SAR402671 (venglustat) administered orally for 4 weeks, as compared to placebo in participants
Parkinson's Diseasevenglustat GZ/SAR402671Placebo
3
hypotheses
Temporal Decoupling via Circadian Clock ResetLysosomal Enzyme Trafficking CorrectionCircadian Clock-Autophagy Synchronization
Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies
NCT03888222 Phase II Completed
Georgetown University 26 enrolled 2019-04-23 → 2021-08-27
This study evaluates the effect of Bosutinib (Bosulif,Pfizer®) in the treatment of patients with Dementia with Lewy Bodies. Half participants will receive 100 mg of Bosutinib , while the other half wi
Dementia With Lewy BodiesPlacebo Oral TabletBosutinib Oral Tablet
3
hypotheses
TREM2 Conformational Stabilizers for Synaptic DiscriminationTREM2 Agonism to Reprogram Infiltrated Monocytes Toward NeurMicroglial TREM2-SYK Pathway Enhancement
The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals
NCT03326648 N/A Completed
Truls Raastad 34 enrolled 2016-09-01 → 2017-12-20
The purpose of this study is to investigate mechanisms underlying the reduction in muscle quality (the ratio between muscle strength and muscle size) with aging, and to investigate how these factors a
SarcopeniaStrength trainingProtein supplementation
3
hypotheses
FOXO3-Longevity Pathway Epigenetic ReprogrammingTFEB-PGC1α Mitochondrial-Lysosomal DecouplingThe Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease
NCT05541627 Phase I Active
Brainvectis, a subsidiary of Asklepios BioPharmace 5 enrolled 2022-10-12 → 2024-04-04
A Phase I/II Dose-Finding Study to Evaluate Striatal Administration of AB-1001 (previously BV-101) in Adults with Early Manifest Huntington's Disease
Huntington DiseaseAB-1001 Gene Therapy
3
hypotheses
CYP46A1 Overexpression Gene TherapyCYP46A1 Suppression for Tau-Mediated NeurodegenerationCYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microgli
Adapting Connect-Home Transitional Care for the Unique Needs of Persons With Alzheimer's Disease and Other Dementias and
NCT05887388 N/A Completed
University of North Carolina, Chapel Hill 38 enrolled 2021-09-10 → 2022-02-27
This primary purpose of this study will be to (1) examine the feasibility and acceptability of transitional care focusing on care needs of skilled nursing facility (SNF) patients with dementia and the
Pathologic ProcessesConnect-Home Plus
3
hypotheses
Prefrontal sensory gating circuit restoration via PV interneHippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Effects of Electroacupuncture on Cognitive Symptoms in Major Depressive Disorder
NCT06239740 N/A Completed
Thammasat University 60 enrolled 2022-12-24 → 2023-01-24
The goal of this pilot Study and Randomized Controlled Trial is to investigate the impact of electroacupuncture on cognitive function, quality of life (QoL), and depression severity in patients with m
Major Depressive DisordersCognitive DysfunctionElectroacupuncture groupSham acupuncture
3
hypotheses
Prefrontal sensory gating circuit restoration via PV interneHippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment
NCT00306124 Phase IV Unknown
University Hospital Muenster 120 enrolled Started 2006-01
This study aims to determine whether levodopa is effective in boosting learning and memory in healthy subjects and patients with dementia or Mild Cognitive Impairment. We also examine in healthy subj
Alzheimer's DiseaseMild Cognitive ImpairmentHealthyLevodopa
3
hypotheses
Prefrontal sensory gating circuit restoration via PV interneHippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
NCT00753662 Phase II Unknown
Tel-Aviv Sourasky Medical Center 45 enrolled 2008-11 → 2012-11
The primary objective of this trial is to assess the ability of Transcranial Magnetic Stimulation with H2 coil to prefrontal and parieto-temporal cortex to improve cognitive performance in patients wi
Alzheimer's Disease1Hz TMS with H2 coil10Hz TMS with H2 coil to prefrontal and SHAM TMS with H2 coil
3
hypotheses
Prefrontal sensory gating circuit restoration via PV interneHippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctu
NCT03391882 Phase III Completed
Sumitomo Pharma America, Inc. 113 enrolled 2018-12-19 → 2021-08-11
A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes) compared to an approved drug used to treat people with P
Motor OFF Episodes Associated With ParkiAPL-130277subcutaneous apomorphine
3
hypotheses
Thalamocortical Synchrony Restoration via NMDA ModulationGlymphatic-Mediated Tau Clearance DysfunctionGluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl
Protective Anesthesiological Management Procedure Imposes Control on Respiratory Comlications
NCT06282003 N/A Unknown
Masa Kontic 53 enrolled 2023-10-10 → 2024-06-30
Anesthetic effects, surgery, and invasive mechanical intubation can impair respiratory function during general anesthesia. The risk factors for postoperative pulmonary complications (PPCs) include the
Well-Being, PsychologicalThe procedure of protective lung ventila
3
hypotheses
Thalamocortical Synchrony Restoration via NMDA ModulationGlymphatic-Mediated Tau Clearance DysfunctionGluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
NCT02168127 Phase III Completed
Rhodes Pharmaceuticals, L.P. 360 enrolled 2014-05 → 2015-05
The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.
ADHDDrug: PRC-063PRC-063
3
hypotheses
Thalamocortical Synchrony Restoration via NMDA ModulationGlymphatic-Mediated Tau Clearance DysfunctionGluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
NCT02632370 N/A Completed
Constantinos Hadjipanayis 69 enrolled 2016-05 → 2018-12-31
In support of the US marketing application for 5-ALA, this single arm trial is being conducted to establish the efficacy and safety of Gliolan® (5-ALA) in patients with newly diagnosed or recurrent ma
Malignant GliomasGliolan®Fluorescence-Guided Surgery
3
hypotheses
Thalamocortical Synchrony Restoration via NMDA ModulationGlymphatic-Mediated Tau Clearance DysfunctionGluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl
Magnetic Resonance Imaging of Brain Development in Autism
NCT00449566 N/A Unknown
UMC Utrecht 300 enrolled Started 2006-01
The purpose of this study is to investigate brain development in autism by longitudinally assessing children with autism, as well as typically developing controls, using advanced MR techniques. We wil
Autism
3
hypotheses
Thalamocortical Synchrony Restoration via NMDA ModulationGlymphatic-Mediated Tau Clearance DysfunctionGluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl
Impacts of Intermittent Fasting on Energy Balance and Associated Health Outcomes
NCT02498002 N/A Completed
University of Bath 54 enrolled 2015-05 → 2018-09-04
Obesity is a global concern with links to conditions such as diabetes. Historically, these conditions have been managed by reducing energy intake on a daily basis, which is often hampered by low adher
ObesityType 2 DiabetesPhysical Activity Monitoring (Actiheart)Energy Intake MonitoringBody Weight Monitoring
2
hypotheses
Perforant Path Presynaptic Terminal Protection StrategyDigital Twin-Guided Metabolic Reprogramming
Comparison of Different Acceleration Modes of Transcranial Magnetic Stimulation
NCT06881030 N/A Not Yet Recruiting
First Affiliated Hospital of Zhejiang University 45 enrolled 2025-03-25 → 2025-08-31
To compare the efficacy and safety of 6 times a day, 10 times a day acceleration mode and sham stimulation intervention for TRD, and to explore the antidepressant mechanism of accelerated mode, so as
Treatment Resistant Depression (TRD)Noninvasive transcranial magnetic stimulNoninvasive transcranial magnetic stimulSham
2
hypotheses
Reelin-Mediated Cytoskeletal Stabilization ProtocolHypocretin-Neurogenesis Coupling Therapy
Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight
NCT01238250 N/A Recruiting
Simons Searchlight 100,000 enrolled 2010-10 → 2050-10
Simons Searchlight is an observational, online, international research program for families with rare genetic variants that cause neurodevelopmental disorders and may be associated with autism. Simons
16P11.2 Deletion Syndrome16p11.2 Duplications1Q21.1 Deletion
2
hypotheses
Reelin-Mediated Cytoskeletal Stabilization ProtocolMitochondrial RNA Granule Rescue Pathway
11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
NCT05608395 Phase II Completed
Masaryk Memorial Cancer Institute 33 enrolled 2020-12-04 → 2024-06-20
Glioblastoma multiforme (GBM) is the most common primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e. radiotherapy, chemotherapy, or
Glioblastoma Multiforme11C-Methionine PET/CT
2
hypotheses
Grid Cell-Specific Metabolic Reprogramming via IDH2 EnhancemGFAP-Positive Reactive Astrocyte Subtype Delineation
Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19
NCT06649227 Phase I Recruiting
University Hospital, Lille 5 enrolled 2025-07-10 → 2029-07-10
Refractory/Relapsed (R/R) acute myeloid leukemia (AML) is associated with a dis-mal prognosis. In some subsets of AML such as AML driven by the t(8;21) translocation, leading to the RUNX1-RUNX1T1 (AM
Relapsed Adult AMLCAR-T cell therapy
2
hypotheses
Grid Cell-Specific Metabolic Reprogramming via IDH2 EnhancemNucleolar Stress Response Normalization
Arimoclomol in ALS (ORARIALS-01)
NCT03491462 Phase III Completed
2
hypotheses
Heat Shock Protein 70 Disaggregase AmplificationStress Granule Phase Separation Modulators
Talazoparib in Glioblastoma
NCT04297683 Phase I Recruiting
2
hypotheses
PARP1 Inhibition TherapyLiquid-Liquid Phase Separation Modifier Therapy
Clonal Hematopoiesis in Giant Cell Arteritis
NCT06244069 N/A Not Yet Recruiting
ASST Fatebenefratelli Sacco 326 enrolled 2024-03 → 2028-03
The goal of this clinical trial is to verify whether CHIP is correlated with the clinical, instrumental, and histological characteristics of GCA, and to characterize the pathogenetic effects of clonal
Giant Cell ArteritisTemporal ArteritisClonal Hematopoiesis of Indeterminate PoTemporal arterial biopsyWhole exome sequencingSingle cell transcriptomics
2
hypotheses
Epigenetic Memory Erasure via TET2 ActivationTET2-Mediated Demethylation Rejuvenation Therapy
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies
NCT03682029 N/A Active
Rigshospitalet, Denmark 109 enrolled 2017-11-21 → 2023-09-27
The primary purpose of this multi-centre, randomized, placebo-controlled, double-blind phase II study is to investigate if oral vitamin C may change the biology of low-risk myeloid malignancies; i.e.,
Myelodysplastic SyndromesChronic Myelomonocytic Leukemia-1CytopeniaVitamin C (ascorbic acid)Placebo
2
hypotheses
Epigenetic Memory Erasure via TET2 ActivationTET2-Mediated Demethylation Rejuvenation Therapy
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
NCT03397173 Phase II Completed
Case Comprehensive Cancer Center 12 enrolled 2018-03-16 → 2021-01-03
The purpose of this study is to evaluate the efficacy of treatment with azacitidine (an FDA approved drug for the treatment of MDS) and high dose ascorbic acid in patients with TET2 mutations. This ap
Myelodysplastic SyndromesMyeloproliferative NeoplasmAcute Myeloid LeukemiaAzacitidineAscorbic acid
2
hypotheses
Epigenetic Memory Erasure via TET2 ActivationTET2-Mediated Demethylation Rejuvenation Therapy
Sterile Inflammation and Molecular Aberrations in MDS
NCT04313231 N/A Unknown
Medical University Innsbruck 130 enrolled 2020-01-22 → 2023-01
The objective of this study is the description of the possible association between genetic mutation/aberration profiles, inflammatory tonus and clinical phenotype based on PROMs and HRQoL. Apart from
Myelodysplastic SyndromesNext Generation SequencingTumorimmunological examinations - multipflow cytometry
2
hypotheses
Epigenetic Memory Erasure via TET2 ActivationTET2-Mediated Demethylation Rejuvenation Therapy
Hydroxyzine and Risk of Prolongation of QT Interval
NCT02814981 N/A Unknown
University Hospital, Caen 130 enrolled 2015-11 → 2017-08
On 04/30/2015, ANSM (the National Security Agency of Medicines and Health Products) shared an information for general practicioners, pediatricians, anesthesiologists, dermatologists, geriatricians, ps
HydroxyzineLong QT Syndrome
2
hypotheses
Metabolic Switch Targeting for A1→A2 RepolarizationMetabolic Reprogramming via Microglial Glycolysis Inhibition
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cance
NCT04644770 Phase I Active
Janssen Research & Development, LLC 144 enrolled 2020-11-12 → 2027-01-15
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the
Prostatic NeoplasmsAdenocarcinomaJNJ-69086420JNJ-78278343Stereotactic body radiation therapy
2
hypotheses
Metabolic Switch Targeting for A1→A2 RepolarizationMetabolic Reprogramming via Microglial Glycolysis Inhibition
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
NCT07082920 Phase I Recruiting
Janssen Research & Development, LLC 140 enrolled 2025-07-07 → 2027-01-28
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine h
Prostatic NeoplasmsJNJ-78278343JNJ-95298177
2
hypotheses
Metabolic Switch Targeting for A1→A2 RepolarizationMetabolic Reprogramming via Microglial Glycolysis Inhibition
Non-specific Effects of Vaccination on Mortality and Morbidity
NCT03176719 N/A Unknown
Radboud University Medical Center 1,005 enrolled 2017-06-17 → 2017-10-31
It has long been recognized that the positive effects of vaccination on childhood mortality cannot be solely attributed to a decline in the disease targeted by the vaccine. These so-called non-specifi
Vaccine ReactionAnemiaMalaria,FalciparumVenipuncture
2
hypotheses
Metabolic Switch Targeting for A1→A2 RepolarizationMetabolic Reprogramming via Microglial Glycolysis Inhibition
Metabolic Reprogramming in Renal Tubular Cells in Acute Kidney Injury Following Severe Trauma
NCT06167512 N/A Recruiting
Assistance Publique - Hôpitaux de Paris 80 enrolled 2024-06-27 → 2025-09-27
Severe trauma remains the leading cause of death in people under 50, and is associated with high morbidity, including severe disability, with a substantial socio-economic impact. Secondary to trauma,
Multi-organ Failure After Severe Trauma
2
hypotheses
Metabolic Switch Targeting for A1→A2 RepolarizationMetabolic Reprogramming via Microglial Glycolysis Inhibition
Internal Biodegradable Stent Versus Non-Stent in Patients at High-Risk of Developing Fistula After Pancreatoduodenectomy
NCT05668260 N/A Recruiting
Ospedale San Raffaele 122 enrolled 2023-01-25 → 2026-07
The aim of this randomized controlled study is to compare the efficacy of biodegradable internal pancreatic stenting versus no stenting in patients undergoing pancreatoduodenectomy (PD), focusing on a
PancreatoduodenectomyClinically Relevant Postoperative PancreInternal Biodegradable Pancreatic StentBiodegradable Stent
2
hypotheses
Magnetosonic-Triggered Transferrin Receptor ClusteringBlood-Brain Barrier SPM Shuttle System
Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury
NCT07236463 Phase I Not Yet Recruiting
Centre Hospitalier Universitaire de Nīmes 14 enrolled 2026-02-01 → 2027-02-01
The goal of this clinical trial is to learn if adding the iron-binding drug MEX-CD1 to dialysis fluid can help remove excess iron in adults with sepsis-associated acute kidney injury (AKI) requiring d
Acute Kidney InjurySepsisContinuous veino-veinous dialysis with i
2
hypotheses
Magnetosonic-Triggered Transferrin Receptor ClusteringBlood-Brain Barrier SPM Shuttle System
S. Japonicum and Pregnancy Outcomes
NCT00486863 Phase II Completed
National Institute of Allergy and Infectious Disea 370 enrolled 2007-08 → 2012-11
The purpose of the study is to understand whether the drug praziquantel (PZQ) is safe for the mother and developing baby when the mother has schistosomiasis (a type of worm) infection, and whether the
SchistosomiasisPraziquantelPlacebo
2
hypotheses
Magnetosonic-Triggered Transferrin Receptor ClusteringBlood-Brain Barrier SPM Shuttle System
Is Helicobacter Pylori Infection a Cause or Treatment Failure of Iron Deficiency Anemia in Children in Bangladesh?
NCT00284700 N/A Completed
International Centre for Diarrhoeal Disease Resear 260 enrolled Started 1997-12
Helicobacter pylori is recognized as a major gastrointestinal pathogen in developing countries. This microorganism infects up to 60% of children less than five years in those countries and is strongly
Helicobacter Pylori InfectionIron Deficiency AnemiaNot Severely MalnourishedIron
2
hypotheses
Magnetosonic-Triggered Transferrin Receptor ClusteringBlood-Brain Barrier SPM Shuttle System
WASH Benefits Bangladesh
NCT01590095 N/A Unknown
International Centre for Diarrhoeal Disease Resear 5,040 enrolled 2012-05 → 2022-12
Brief Summary: The purpose of this study is to measure the independent and combined effects of interventions that improve water quality, sanitation, hand washing, and nutrition on child growth and de
MalnutritionDiarrheaChild DevelopmentWater qualitySanitationHand washing
2
hypotheses
Magnetosonic-Triggered Transferrin Receptor ClusteringBlood-Brain Barrier SPM Shuttle System
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study
NCT05245344 N/A Unknown
Neuromed IRCCS 154 enrolled 2022-04-01 → 2023-06-30
This is a prospective non interventional study including patients with Relapsing-Remitting Multiple Sclerosis (RRMS) or with Neuromyelitis Optica Spectrum Disorders (NMOSD) and healthy subjects, who a
Relapsing-Remitting Multiple Sclerosis (Neuromyelitis OpticaHealthyPeripheral blood withdrawal
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte My
NCT06865274 N/A Recruiting
Fondazione Policlinico Universitario Agostino Geme 50 enrolled 2025-02-20 → 2026-02-28
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody asso
Neuromyelitis Optica Spectrum DisordersMOGADMultiple SclerosisBlood draw for the laboratory assessment
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China
NCT03514030 N/A Unknown
Beijing Tongren Hospital 400 enrolled 2018-04-01 → 2020-04
In 1894, Devic first proposed the concept of neuromyelitis optica(NMO). NMO is an inflammatory demyelinating disease that selectively affects the central nervous system of the optic nerve and spinal c
NMO Spectrum Disorder;Registry Studyserum AQP4-antibody testing method
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders
NCT04101058 N/A Unknown
Third Affiliated Hospital, Sun Yat-Sen University 200 enrolled 2019-01-21 → 2020-01-02
Neuromyelitis Optica (NMO)/ Neuromyelitis Optica Spectrum Disorders (NMOSD) is an immune-mediated inflammatory demyelinating disease of the central nervous system mainly involving optic nerve and spin
Neuromyelitis Optica Spectrum Disorders
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
NCT06673394 Phase II Withdrawn
Tianjin Medical University General Hospital 2025-09-03 → 2026-06-01
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory autoimmune disorder of the central nervous system characterized by the pathogenic anti-aquaporin 4 antibody (AQP4-IgG). The
Neuromyelitis Optica Spectrum Disorder AComplement protein C5 inhibitorIVMP
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Inectolizumab With Steroid Optimization in Newly Treated NMOSD
NCT07159893 N/A Not Yet Recruiting
First Affiliated Hospital of Wenzhou Medical Unive 25 enrolled 2025-09 → 2026-05
Title: Study of Inectolizumab Combined With Steroid Hormone Adjustment Strategies in Treatment-naive Patients With Neuromyelitis Optica Spectrum Disease Objective:This study aims to evaluate the stero
Neuromyelitis OpticaAutoimmune DiseasesDemyelinating Autoimmune Diseases, CNSInebilizumab + Rapid Steroid Tapering grInebilizumab + Standard Steroid Tapering
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles.
NCT07361887 N/A Recruiting
University of Seville 8 enrolled 2025-11-01 → 2025-12-01
This study aims to investigate how moderate wine consumption influences circulating extracellular vesicles (EVs) in healthy adults. EVs are small particles released by cells that carry proteins, lipid
Atherosclerosis Cardiovascular DiseaseObesityMetabolic SyndromeWhite WineRed WineWater
2
hypotheses
Piezoelectric Nanochannel BBB DisruptionVascular-Glial Interface Restoration
BIIB078 (C9orf72 ASO) in ALS
NCT03568578 Phase I Completed
2
hypotheses
Phase-Separated Organelle TargetingStress Granule Phase Separation Modulators
Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disea
NCT07467460 N/A Recruiting
Neuromed IRCCS 500 enrolled 2026-02-17 → 2028-09-30
In recent decades, advances in medicine have significantly improved both quality of life and life expectancy. However, these positive effects are also associated with a considerable increase in the pr
PARKINSON DISEASE (Disorder)Alzheimer s DiseaseDiabete Type 2
2
hypotheses
Temporal Decoupling via Circadian Clock ResetCircadian Clock-Autophagy Synchronization
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
NCT05356104 Phase II Recruiting
Chinese University of Hong Kong 110 enrolled 2022-05-25 → 2026-05
Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be su
Cerebral Small Vessel DiseaseExenatide extended release
2
hypotheses
Temporal Decoupling via Circadian Clock ResetCircadian Clock-Autophagy Synchronization
Transcranial Alternating Current Stimulation in Lewy Body Dementia
NCT07375771 N/A Recruiting
IRCCS Centro San Giovanni di Dio Fatebenefratelli 40 enrolled 2025-10-01 → 2027-09
The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of transcranial alternating current stimulation
Lewy Body Dementia (LBD)Transcranial Alternating Current StimulaTranscranial Alternating Current StimulaSham Transcranial Alternating Current St
2
hypotheses
Temporal Decoupling via Circadian Clock ResetCircadian Clock-Autophagy Synchronization
WHIte MAtter Hyperintensity Shape and Glymphatics
NCT06010511 N/A Recruiting
Leiden University Medical Center 50 enrolled 2023-01-18 → 2026-08-30
In a society with increased life expectancy, the economic, social and personal burden of dementia increases. Dementia is often caused by a combination of neurovascular and neurodegenerative diseases.
Cerebral Small Vessel DiseasesDementia, MixedDementia, Vascular3T MRI scan7T MRI scanNeuropsychological assessment
2
hypotheses
Temporal Decoupling via Circadian Clock ResetCircadian Clock-Autophagy Synchronization
Daily Intake of Multivitamin & Mineral Supplementation Effects on Biological Age of Relatively Healthy Middle-aged Indiv
NCT06666660 N/A Recruiting
National University of Singapore 400 enrolled 2024-09-23 → 2025-04-30
Micronutrients, such as vitamins and minerals, are required to sustain fundamental physiological processes in individuals. As individuals age, the risk of having suboptimal levels of micronutrients in
Relatively Healthy VolunteersMultivitamin/Mineral supplementsPlacebo
2
hypotheses
Temporal Decoupling via Circadian Clock ResetCircadian Clock-Autophagy Synchronization
fNIRS Studies of Music Intervention of Parkinson's Disease
NCT04212897 N/A Unknown
The First Affiliated Hospital of Dalian Medical Un 150 enrolled 2021-01-18 → 2021-12
Functional near-infrared spectroscopy (fNIRS) will be used to monitor neuronal activities and connectivity to elucidate the correlation between physiological changes within the brain and the benefits
Parkinson DiseaseMusic Therapy
2
hypotheses
Temporal Decoupling via Circadian Clock ResetCircadian Clock-Autophagy Synchronization
Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil
NCT00670813 Phase II Withdrawn
Technical University of Munich 30 enrolled 2008-05 → 2009-11
The study aims to investigate whether the administration of the stimulant modafinil during a 40 hour sleep deprivation period in depressed patients can intensify the antidepressant effect of the sleep
DepressionModafinil (Vigil)Placebo
2
hypotheses
Temporal Decoupling via Circadian Clock ResetCircadian Clock-Autophagy Synchronization
Frailty Prevention in Elders From Reunion Island
NCT05090241 N/A Completed
Universite de La Reunion 147 enrolled 2021-11-01 → 2023-12-27
In Reunion Island, people encounter environmental and social conditions leading to premature ageing and subsequent frailty. The study evaluates tools, supported by the latest scientific advances in "
Geriatric AssessmentFrail Elderly SyndromePreventionInstrumental measurement of balance and
2
hypotheses
Temporal Decoupling via Circadian Clock ResetCircadian Clock-Autophagy Synchronization
Precision Medicine in the Treatment of Epilepsy
NCT05450822 N/A Recruiting
Gitte Moos Knudsen 550 enrolled 2022-02-18 → 2026-12-31
Primary objectives: The purpose of this study is to identify single and composite biomarkers (from neuroimaging, electrophysiological, and non-imaging biological measures), clinical measures (from co
EpilepsyLevetiracetamLevetiracetam TabletsLamotrigine tablet
2
hypotheses
Biorhythmic Interference via Controlled Sleep OscillationsSynaptic Vesicle Tau Capture Inhibition
A Study of PY314 in Subjects With Advanced Solid Tumors
NCT04691375 Phase I Terminated
Ikena Oncology 86 enrolled 2020-10-29 → 2023-08-31
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standa
Advanced Solid TumorGynecologic CancerBreast CancerPY314Combination Therapy: PY314 + Pembrolizum
2
hypotheses
TREM2 Conformational Stabilizers for Synaptic DiscriminationCell-Type Specific TREM2 Upregulation in DAM Microglia
Predictive Role of sTREM in Endovascular Thrombectomy Outcomes
NCT06545591 N/A Recruiting
The Affiliated Hospital of Xuzhou Medical Universi 300 enrolled 2024-07-01 → 2027-12-31
Soluble triggering receptor expressed on myeloid cells (sTREM), which reflects microglia activation, has been reported closely associated with neuronal injury and neuroinflammation. This study is to i
Acute Ischemic Stroke
2
hypotheses
TREM2 Conformational Stabilizers for Synaptic DiscriminationCell-Type Specific TREM2 Upregulation in DAM Microglia
Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy
NCT05521737 N/A Recruiting
Instituto Mexicano del Seguro Social 200 enrolled 2021-11-01 → 2024-12
This is a controlled clinical trial with the aim to study the effects of electroacupuncture on neuropathic pain reduction, quality of life and changes in sensory and motor nerve conduction velocity in
ElectroacupunctureAcupunctureDiabetic PolyneuropathyElectroacupunctureSham Acupuncture
2
hypotheses
Optogenetic Microglial Deactivation via Engineered InhibitorGAP43-mediated tunneling nanotube stabilization enhances neu
Suvorexant and Glymphatic Function (MRI study)
NCT03289143 Phase IV Completed
2
hypotheses
Matrix Stiffness Normalization via Targeted Lysyl Oxidase InAPOE-Dependent Autophagy Restoration
A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.
NCT06823752 Phase II Recruiting
Woolcock Institute of Medical Research 20 enrolled 2025-05-13 → 2026-04
The goal of this clinical trial is to explore the potential neuroprotective benefits of a dual orexin receptor antagonist (DORA) in adults with insomnia. The main questions it aims to answer are: * D
InsomniaLemborexant 10 MGPlacebo
2
hypotheses
Orexin-Microglia Modulation TherapyHypocretin-Neurogenesis Coupling Therapy
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Di
NCT02565511 Phase II Terminated
Novartis Pharmaceuticals 480 enrolled 2015-11-30 → 2020-04-30
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated wit
Alzheimers DiseaseCAD106 ImmunotherapyPlacebo to CAD106CNP520
2
hypotheses
Palmitoylation-Targeted BACE1 Trafficking DisruptorsGlymphatic-Mediated Tau Clearance Dysfunction
DORA and LP in Alzheimer's Disease Biomarkers
NCT06274528 Phase II Recruiting
Washington University School of Medicine 201 enrolled 2024-03-11 → 2029-03-11
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leadi
Alzheimer DiseaseLemborexant 10 mgLemborexant 20mgPlacebo
2
hypotheses
TREM2-mediated microglial tau clearance enhancementCell-Type Specific TREM2 Upregulation in DAM Microglia
Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment
NCT07027072 Phase II Recruiting
NeuroBiogen Co., Ltd 114 enrolled 2025-08-06 → 2027-06-30
A randomized, double-blind, placebo-controlled, dose-finding Phase 2a clinical trial will be conducted to evaluate the efficacy and safety of KDS2010 in patients with Mild Cognitive Impairment (MCI) d
Mild Cognitive Impairment (MCI)Mild DementiaAlzheimer&#39;s DiseaseKDS2010Placebo
2
hypotheses
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Benefits of Nicotinamide Riboside Upon Cognition and Sleep
NCT05500170 N/A Recruiting
State University of New York at Buffalo 50 enrolled 2023-04-04 → 2027-08-30
Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the avail
Cognitive ImpairmentSleep QualityNicotinamide ribosidePlacebo
2
hypotheses
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia
NCT02862210 Phase II Completed
Columbia University 17 enrolled 2017-01-27 → 2022-11-20
Frontotemporal dementia (FTD) is a progressive neurodegenerative illness that affects the frontal and anterior temporal lobes of the brain. Changes in behavior, including agitation, aggression, and re
Frontotemporal Dementia (FTD)Lithium CarbonatePlacebo
2
hypotheses
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Evolving Methods to Combine Cognitive and Physical Training for Individuals With Mild Cognitive Impairment
NCT02512627 N/A Completed
Chang Gung Memorial Hospital 55 enrolled 2015-01-30 → 2018-01-29
This study aims to investigate and compare the intervention effects of combining exercise and cognitive training (either sequentially or simultaneously in a dual-task paradigm) in elderly with mild co
Mild Cognitive ImpairmentCognitive trainingPhysical exercise
2
hypotheses
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Acute Effects of Mango Leaf Extract (Zynamite®) on Cognitive Function, Mood and Stress
NCT04299217 N/A Completed
Northumbria University 75 enrolled 2019-11-04 → 2020-03-17
This study aims to assess the effects of a single dose of Zynamite® on performance across a number of cognitive domains (attention, working memory, episodic memory, executive function), as well as dur
Cognitive ChangeStressZynamite®Placebo
2
hypotheses
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Impact of Levagen+® Palmitoylethanolamide (PEA) in a Cross-Over Trial Examining Stress and Cognition in University Stude
NCT06225440 N/A Completed
University of Westminster 64 enrolled 2022-09-01 → 2023-12-31
The goal of this randomised cross-over trial is to learn about the effects of Levagen+® Palmitoylethanolamide (PEA) supplementation on cognition, wellness and well-being in young and healthy universit
Wellness, PsychologicalWell-Being, PsychologicalLevagen+® Palmitoylethanolamide (PEA)Placebo
2
hypotheses
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Combined Technology Enhanced Home Exercise Program and Other Non-pharmacological Intervention for Cancer Survivors
NCT03576274 N/A Completed
Sidney Kimmel Comprehensive Cancer Center at Johns 110 enrolled 2019-10-10 → 2024-09-15
A 12 weeks technology enhanced home exercise (TEHE) program using mobile technologies that provide immediate feedback and send reminder messages to improve exercise motivation is developed. Investigat
Cancer-related Problem/ConditionExerciseAcupressureTechnology Enhanced Home Exercise (TEHE)Auricular Point Acupressure (APA)Mindfulness body scan (MBI)
2
hypotheses
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Combined Effects of Aerobic Exercise and Cognitive Training on Cognition After Stroke
NCT01674790 N/A Completed
Marilyn MacKay-Lyons 22 enrolled 2013-10-13 → 2017-06-16
The objective of the 'Exploring potential synergistic effects of aerobic exercise and cognitive training on cognition after stroke' pilot trial is to investigate the combined effects of aerobic and co
StrokeAerobic trainingCognitive trainingRange of motion exercise
2
hypotheses
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder
NCT04231708 Phase II Not Yet Recruiting
Wayne State University 20 enrolled 2026-10 → 2028-12
This preliminary study is designed to evaluate mechanisms by which excitatory dorsolateral prefrontal cortex (dlPFC) repetitive transcranial magnetic stimulation (rTMS) (vs. sham) and pharmacological
Opioid Use DisorderYohimbine + HydrocortisoneActive rTMSPlacebo
2
hypotheses
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals
NCT01805518 Phase I Completed
Woodbury, Michel, M.D. 20 enrolled 2011-06 → 2012-03
Phosphodiesterase is a candidate for the Rx \& prevention of cognitive and psychotic disorders. Since caffeine targets primarily PDE4(Phosphodiesterase subtype 4), caffeine analogs have been developed
Adverse Mental/Physical Effects of Low DScelectium Tortuosum
2
hypotheses
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
The Effect of Tai Chi and Therapy by Dance and Movement on Blood Irisin Levels in Older Adults Over 65 Years of Age.
NCT05363228 N/A Unknown
Charles University, Czech Republic 90 enrolled 2021-08-01 → 2023-01-30
The aim of this project is to estimate the effects of therapy with dance and movement and Tai Chi on irisin plasma levels, a myokine with proven neuroprotective effects, in the context of baseline lev
Memory DeficitsAgingCognitive ImpairmentTherapy by Dance and MovementTai Chi
2
hypotheses
Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
MCT Oil Supplementation in Early Alzheimer's Disease
NCT04466735 Phase II Completed
Alzheimer DiseaseMedium Chain Triglycerides
2
hypotheses
Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic UncoupliThe Glial Ketone Metabolic Shunt Hypothesis
CRISPR Base Editing for Sickle Cell (BEAM-101)
NCT05398029 Phase I/II Active
2
hypotheses
Epigenetic Memory Reprogramming for Alzheimer's DiseaseAPOE Isoform Conversion Therapy
Colchicine for Amyotrophic Lateral Sclerosis
NCT03693781 Phase II Completed
Azienda Ospedaliero-Universitaria di Modena 54 enrolled 2019-04-10 → 2022-04-14
The study evaluates the effects of two different Colchicine doses (0.01mg/kg/day or 0.005 mg/kg/day) compared to placebo in Amyotrophic Lateral Sclerosis (ALS) patients. Disease progression as defined
Amyotrophic Lateral SclerosisColchicine 1 MG Oral TabletColchicine 1 MG Oral TabletPlacebo Oral Tablet
2
hypotheses
TFEB-PGC1α Mitochondrial-Lysosomal DecouplingThe Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
NCT06335771 N/A Recruiting
Bettina Mittendorfer 60 enrolled 2024-08-01 → 2028-03
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The
ObesityNonalcoholic Fatty LiverDiabetes Type 2Dietary consultation weight loss interve
2
hypotheses
TFEB-PGC1α Mitochondrial-Lysosomal DecouplingThe Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
NCT06571474 Unknown Recruiting
Bettina Mittendorfer 60 enrolled 2024-08-01 → 2028-03
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The
ObesityNon-Alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2
2
hypotheses
TFEB-PGC1α Mitochondrial-Lysosomal DecouplingThe Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Sodium Phenylbutyrate-Taurursodiol (AMX0035) for ALS
NCT02967562 Phase III Completed
2
hypotheses
Targeted Butyrate Supplementation for Microglial Phenotype MProteostasis Enhancement via APOE Chaperone Targeting
Mitochondrial Function Biomarkers in Neurodegeneration
NCT04681943 Observational Recruiting
2
hypotheses
PINK1/Parkin-Independent Mitophagy Bypass for Enhanced DonorGap Junction Hemichannel Modulation for Controlled Mitochond
The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function
NCT00526968 Phase I Completed
Evotec Neurosciences GmbH 19 enrolled 2007-09 → 2007-12
The purpose of this study is to investigate the neurophysiological changes following single doses of EVT 101 using fMRI during rest and during cognitive tasks in young healthy male subjects.
Human VolunteersEVT 101EVT 101placebo
2
hypotheses
Thalamocortical Synchrony Restoration via NMDA ModulationGluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl
The Dortmund Vital Study: Impact of Biological and Lifestyle Factors on Cognitive Performace and Work Ability
NCT05155397 N/A Active
Technical University of Dortmund 627 enrolled 2016-04 → 2035-12
The goal of the Dortmund Vital Study is to validate previous hypotheses and to generate and validate new hypotheses about the relationship of ageing, working conditions, genetic makeup, stress, metabo
Age-related Cognitive Decline
2
hypotheses
Thalamocortical Synchrony Restoration via NMDA ModulationGluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl
DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil
NCT02711683 N/A Completed
First Affiliated Hospital Xi'an Jiaotong Universit 92 enrolled 2016-03 → 2019-12
Alzheimer's disease (AD) is the commonest cause of dementia. There is no effective treatment to cure the disease. Cholinesterase inhibitors, such as donepezil, are widely recommended to patients with
Alzheimer's DiseaseDL-3-n-butylphthalideDonepezil
2
hypotheses
Thalamocortical Synchrony Restoration via NMDA ModulationGluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl
Comfortage - AD Prevention Strategies
NCT06896201 N/A Not Yet Recruiting
Fondazione Policlinico Universitario Agostino Geme 200 enrolled 2025-09 → 2027-03
Study is Interventional, cross-sectional, clinical trial without drug and without device
Alzheimer DiseaseSubjective Cognitive ImpairmentMild Cognitive ImpairmentNeuropsychological Assessments and OtherBlood Exams, Fluid Biomarkers, GeneticsConnectivity Analysis
2
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Lipidation Enhancement Therapy
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
NCT00676143 Phase III Terminated
Pfizer 1,100 enrolled 2008-01 → 2012-10
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each pa
Alzheimer Diseasebapineuzumabplacebo
2
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Lipidation Enhancement Therapy
Cognitive Function in Obstructive Sleep Apnea
NCT07364318 N/A Recruiting
Comenius University 30 enrolled 2024-11-01 → 2027-08-31
Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and has been increasingly recognized as a contributor to cognitive decline and a potential risk factor for neurodegene
OSA - Obstructive Sleep ApneaCognitive Functions
2
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Lipidation Enhancement Therapy
The Swedish BioFINDER Study
NCT01208675 N/A Completed
Skane University Hospital 1,150 enrolled 2010-09 → 2024-12
The present study aims at combining biochemical methods with various types of imaging techniques to identify the pathophysiology of Alzheimer's disease (AD). The main interest is to find markers assoc
Mild Cognitive ImpairmentAlzheimer's DiseaseDementia With Lewy Bodies
2
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Lipidation Enhancement Therapy
Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease
NCT01841905 N/A Unknown
Rhode Island Hospital 60 enrolled 2013-07 → 2016-12
The investigators are conducting a study to try to improve our ability to identify older adults who are at high-risk for progression to Alzheimer's disease, several years before they have symptoms tha
Alzheimer's DiseaseObservational Study
2
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Lipidation Enhancement Therapy
Exploring to Remediate Behavioral Disturbances of Spatial Cognition
NCT05944601 N/A Active
Istituto Auxologico Italiano 83 enrolled 2023-03-01 → 2024-02-28
Spatial navigation (SN) has been reported to be one of the first cognitive domains to be affected in Alzheimer's disease (AD), which occurs as a result of progressive neuropathology involving specific
Spatial NavigationVirtual and computer-based cognitive rem
2
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Lipidation Enhancement Therapy
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
NCT00348309 N/A Completed
GlaxoSmithKline 1,496 enrolled 2006-07-06 → 2009-01-01
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucos
Alzheimer's DiseaseRosiglitazone Extended Release 2mgRosiglitazone Extended Release 8mgPlacebo
2
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Lipidation Enhancement Therapy
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
NCT00043979 Phase II Completed
National Cancer Institute (NCI) 60 enrolled 2002-09-19 → 2009-05-01
This study will examine the safety and effectiveness of stem cell transplantation for treating patients with sarcomas (tumors of the bone, nerves, or soft tissue). Stem cells are immature cells in the
SarcomaF-18 Fluorodeoxyglucosetherapeutic allogeneic lymphocytescyclophosphamide
2
hypotheses
TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between SContext-Dependent Cx43 Modulation Based on Disease Stage
Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients
NCT03045627 Phase II Unknown
Shandong University 120 enrolled 2017-01 → 2018-01
Most of patients with acute myeloid leukemia (AML) are elder and have poor prognosis despite induction chemotherapy.The regimen of cytarabine(Ara-C), aclarubicin and G-CSF (CAG regimen ) has been wide
Acute Myeloid LeukemiaAraCAclarubicinPeg-G-CSF
2
hypotheses
TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between SContext-Dependent Cx43 Modulation Based on Disease Stage
Training Intervention in the Treatment of Anorexia Nervosa
NCT04185727 N/A Terminated
Mental Health Centre Copenhagen, Bispebjerg and Fr 5 enrolled 2019-12-05 → 2020-07-01
The scope of the STRONG\_2 project is to investigate the effect of supervised exercise as add-on to standard of care (SOC), for patients with eating disorders (EDs). The effect of supervised strength
Anorexia NervosaExerciseSupervised strength training
2
hypotheses
TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between SContext-Dependent Cx43 Modulation Based on Disease Stage
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
NCT05855083 Phase II Recruiting
Omeros Corporation 18 enrolled 2023-05-01 → 2025-12
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
Thrombotic MicroangiopathiesHematopoietic Stem Cell TransplantationBiological: narsoplimab
2
hypotheses
TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between SContext-Dependent Cx43 Modulation Based on Disease Stage
A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women
NCT03640754 Phase I Completed
MenoGeniX, Inc. 61 enrolled 2018-08-06 → 2022-01-21
The purpose of this study is to assess the efficacy and safety of repeated administration of G-CSF for the treatment of hot flashes and vasomotor symptoms in women with naturally-occurring or surgical
Postmenopausal SymptomsG-CSFPlacebo/Saline
2
hypotheses
TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between SContext-Dependent Cx43 Modulation Based on Disease Stage
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
NCT04388254 Phase II Completed
Cassava Sciences, Inc. 220 enrolled 2020-03-24 → 2023-11-09
A two-year safety study of simufilam (PTI-125) 100 mg oral tablets twice daily for participants of the previous simufilam studies as wells as additional new mild-to-moderate Alzheimer's disease subjec
Alzheimer DiseaseSimufilam 100 mg oral tabletPlacebo
2
hypotheses
TREM2 Agonism to Reprogram Infiltrated Monocytes Toward NeurMicroglial TREM2-SYK Pathway Enhancement
The Analysis of Gene Variants Related to POCD in Elderly Patients
NCT05419596 N/A Unknown
Istanbul University 126 enrolled 2022-07-01 → 2023-07-01
The pathophysiology of postoperative cognitive dysfunction (POCD) following surgery may be related to Alzheimer's disease. Different studies show that; low levels of glial cell line-derived growth fac
Cognitive DysfunctionUrologic Surgery
2
hypotheses
TREM2 Agonism to Reprogram Infiltrated Monocytes Toward NeurMicroglial TREM2-SYK Pathway Enhancement
Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
NCT01018927 N/A Terminated
University of Arkansas 44 enrolled 2009-06 → 2017-05-30
The purpose of this study is to see if MRI techniques can be used for early evaluation of cardiac amyloidosis which is sometimes seen in individuals with multiple myeloma. Cardiac amyloidosis is a med
Multiple MyelomaAdministering three additional MRI image
2
hypotheses
APOE4-Specific Lipidation Enhancement TherapyDual-Receptor Antibody Shuttling
Post-stroke Cognitive Impairment and Dementia
NCT01339195 N/A Completed
Centre Hospitalier Universitaire, Amiens 1,635 enrolled 2010-08 → 2016-12
Projections from epidemiological studies suggest that, among the Western adult population, one in three will present a cerebrovascular accident (stroke), severe cognitive disorders, or both. To better
StrokeCognitive DisordersBehavioral DisordersFrench adaptation of NINDS-Canadian Stro
2
hypotheses
APOE4-Specific Lipidation Enhancement TherapyDual-Receptor Antibody Shuttling
A Study Investigating the Effectiveness of a LifeSeasons NeuroQ Supplement With Lifestyle Changes to Improve Cognitive F
NCT04149639 N/A Completed
LifeSeasons Inc. 40 enrolled 2019-11-08 → 2020-07-07
The objective of this study is to evaluate the efficacy of a NeuroQ supplement designed by Dr. Bredesen to complement his Lifestyle modification protocol. Eligible participants will be expected to con
HealthyNeuroQ
2
hypotheses
APOE4-Specific Lipidation Enhancement TherapyDual-Receptor Antibody Shuttling
Improving Caregiver Mediated Medication Management- The 3M Study
NCT03127930 N/A Completed
University of Pittsburgh 183 enrolled 2010-06-01 → 2013-07-30
This study sought to improve medication management by caregivers of community dwelling patients with dementia or simple memory loss. This was done by testing a tailored intervention delivered both in-
Medication ManagementIntervention
2
hypotheses
APOE4-Specific Lipidation Enhancement TherapyDual-Receptor Antibody Shuttling
Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their Caregivers
NCT00255866 Phase II Completed
University of Washington 90 enrolled 2004-01 → 2006-12
This study will develop a treatment program to reduce mood and behavior problems in assisted living residents who have dementia.
DementiaAlzheimer DiseaseSkills training for the care of dementia
2
hypotheses
APOE4-Specific Lipidation Enhancement TherapyDual-Receptor Antibody Shuttling
Brain Inflammation in Major Depressive Disorder Background
NCT01851356 N/A Completed
National Institute of Mental Health (NIMH) 61 enrolled 2013-05-08 → 2017-07-27
Background: \- Studies have shown that inflammation plays an important role in depression. Brain inflammation may contribute to depression, and may make it more difficult to treat some kinds of depre
Major Depression
2
hypotheses
IL-10-Producing B10 Cells Establish AQP4-Specific PeripheralAryl Hydrocarbon Receptor (AHR) Activation in B Cells Determ
EPIMix Versus CT Brain Pediatric Study
NCT03847051 N/A Completed
Karolinska University Hospital 15 enrolled 2019-02-15 → 2020-03-10
This study aims to assess the diagnostic feasibility and diagnostic performance of a new fast MR sequence EPIMix for neuroradiological evaluation in comparison to computed tomography of brain in pedia
Brain DiseasesMRI
2
hypotheses
IL-10-Producing B10 Cells Establish AQP4-Specific PeripheralAryl Hydrocarbon Receptor (AHR) Activation in B Cells Determ
Cilostazol in Parkinson&#39;s Disease
NCT06612593 Phase II Not Yet Recruiting
Ain Shams University 50 enrolled 2024-10-01 → 2025-10-01
Parkinson's disease is the second most common neurodegenerative diseases. The conventional treatment for PD has included dopaminergic treatment as Levodopa\\carbidopa or dopamine agonists, anti-cholin
Parkinson's DiseaseCilostazolPlaceboStandard treatment
2
hypotheses
IL-10-Producing B10 Cells Establish AQP4-Specific PeripheralAryl Hydrocarbon Receptor (AHR) Activation in B Cells Determ
Female Concussion Head Cooling
NCT07303933 N/A Not Yet Recruiting
Penn State University 32 enrolled 2026-01-15 → 2027-01-01
This research is being done to examine the benefits of a 28 day head cooling intervention on cognition, inflammation of the brain, sleep quality, menstrual symptom interaction, and mood in acutely con
Concussion (Diagnosis)Concussion Post SyndromeConcussion, MildBrain Cooling
2
hypotheses
IL-10-Producing B10 Cells Establish AQP4-Specific PeripheralAryl Hydrocarbon Receptor (AHR) Activation in B Cells Determ